Alan Ashworth's guest appearances

Alan Ashworth

Breast Cancer Update

Investigating Breast Cancer

Larry Norton

Mark Robson

Jack Cuzick

Luca Gianni

Kent Osborne

Walter Willett

Michael Clarke

Norman Wolmark

Emmanuel S Antonarakis

Johanna Bendell

Ian E Krop

Andrew McKenzie

Richard Peto

Mina Bissell

Lawrence Shulman

OwlTail

It sounds like something out of Game of Thrones: Attack the weakness. Today, we apply the phrase to a more important and real battle – the one against breast cancer.  As you’ll hear, Dr. Alan Ashworth is part of a team that developed something called PARP Inhibitors and, quite creatively, identified ways to use them to attack the weaknesses of various cancers, including breast cancer. As a recent new report noted, “with three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.”  How do PARP Inhibitors work and what might they mean for attacking cancers’ weaknesses?  That’s just part of what I discussed with Dr. Ashworth.   Some background: He’s the President, UCSF Helen Diller Family Comprehensive Cancer Center; Senior Vice President for Cancer Services of UCSF Health; and a Professor in the Division of Hematology/Oncology at UCSF’s Department of Medicine. Dr. Ashworth is an elected member of EMBO, the Academy of Medical Sciences, and a Fellow of the Royal Society. He has won a number of the world’s leading scientific prizes and awards, and he’s also a BCRF Investigator since 2008.

It sounds like something out of Game of Thrones: Attack the weakness. Today, we apply the phrase to a more important and real battle – the one against breast cancer. As you’ll hear, Dr. Alan Ashworth is part of a team that developed something called PARP Inhibitors and, quite creatively, identified ways to use them to attack the weaknesses of various cancers, including breast cancer. As a recent new report noted, “with three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.” How do PARP Inhibitors work and what might they mean for attacking cancers’ weaknesses? That’s just part of what I discussed with Dr. Ashworth.   Some background: He’s the President, UCSF Helen Diller Family Comprehensive Cancer Center; Senior Vice President for Cancer Services of UCSF Health; and a Professor in the Division of Hematology/Oncology at UCSF’s Department of Medicine. Dr. Ashworth is an elected member of EMBO, the Academy of Medical Sciences, and a Fellow of the Royal Society. He has won a number of the world’s leading scientific prizes and awards, and he’s also a BCRF Investigator since 2008.

Attacking cancer's weaknesses, with Dr. Alan Ashworth

Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Professor Alan Ashworth, FRS conducted by Neil Love, MD. Produced by Research To Practice.

BCU1 2011 | Interview with Professor Alan Ashworth, FRS